Key result
Off-label use of drug-eluting stents is associated with increased risks of early and late stent thrombosis, death, and myocardial infarction compared with on-label use.
Why the study?
Does off-label use of drug-eluting stents increase the risk of stent thrombosis and adverse clinical events compared to on-label use?
Population
Patients receiving drug-eluting stents
Comparison
Off-label use of drug-eluting stents vs On-label use of drug-eluting stents
Design
Editorial
Authors
Loading...
Off-label use of drug-eluting stents carries a higher risk of stent thrombosis and major adverse cardiovascular events compared to on-label use, necessitating careful patient selection.
Does off-label use of drug-eluting stents increase the risk of stent thrombosis and adverse clinical events compared to on-label use?
Off-label use of drug-eluting stents carries a higher risk of stent thrombosis and major adverse cardiovascular events compared to on-label use, necessitating careful patient selection.
Farb et al. (2007) conducted an editorial in Coronary artery disease requiring stenting. Off-label use of drug-eluting stents vs. On-label use of drug-eluting stents was evaluated on Early and late stent thrombosis, death, or myocardial infarction. Off-label use of drug-eluting stents is associated with increased risks of early and late stent thrombosis, death, and myocardial infarction compared with on-label use.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: